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Abstract
The purpose of this study was to investigate the antitumor effects of a combination of metronomic
doses of a novel delivery vehicle, PLGA-PRINT nanoparticles containing docetaxel, and anti-
angiogenic mEZH2 siRNA incorporated into chitosan nanoparticles. In vivo dose-finding studies
and therapeutic experiments were conducted in well-established orthotopic mouse models of
epithelial ovarian cancer. Antitumor effects were determined on the basis of reduction in mean
tumor weight and number of metastatic tumor nodules in the animals. The tumor tissues from
these in vivo studies were stained to evaluate the proliferation index (Ki67), apoptosis index
(cleaved caspase 3), and microvessel density (CD31). The lowest dose of metronomic regimen
(0.5 mg/kg) resulted in significant reduction in tumor growth. The combination of PLGA-PRINT-
docetaxel and CH-mEZH2 siRNA showed significant antitumor effects in the HeyA8 and
SKOV3ip1 tumor models (p<0.05). Individual as well as combination therapies showed
significant anti-angiogenic, anti-proliferative, and pro-apoptotic effects, and combination therapy
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had additive effects. Metronomic delivery of PLGA-PRINT-docetaxel combined with CH-mEZH2
siRNA has significant antitumor activity in preclinical models of ovarian cancer.
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Introduction
Conventional chemotherapeutic regimens involve high doses of a cytotoxic agent followed
by a 3- to 4-week rest period. Such scheduling was believed to be important to balance the
drug’s toxic effects on the tumor and on the host. However, recent studies using this
approach have demonstrated a rapid acquisition of chemoresistance in certain patient
populations after an initial response (1). Furthermore, conventional chemotherapy drugs
have been associated with many toxic adverse effects that often impair quality of life and
limit continuation of therapy (2).
Angiogenesis, or the formation of new blood vessels, has been shown to be vital for cancer
growth and dissemination, thus making it an attractive target for anticancer therapies.
Although standard chemotherapies target the highly proliferating cancer cells, they have
little effect on the slowly dividing endothelial cells (2–4). In addition, the resting period
between chemotherapy cycles allows the tumor endothelium to continue forming new
vessels (2). However, the advent of metronomic dosing, which involves more frequent
administration of low chemotherapeutic doses, has demonstrated the potential for more
pronounced antitumor and anti-angiogenic effects than use of standard maximum tolerated
dose (MTD) chemotherapy (5).
Particle replication in non-wetting templates (PRINT®) is a recently developed method of
fabricating nanocarriers to efficiently deliver therapeutic moieties. This soft lithography
process allows control of various parameters of the nanoparticles such as size, shape, and
composition and thus allows more flexibility than do other approaches (6). Previous reports
have shown that docetaxel incorporated in poly (lactic acid-co-glycolic acid) (PLGA)-
PRINT nanoparticles has higher plasma exposure, greater intratumor accumulation than
docetaxel alone (7).
Enhancer of Zeste Homolog 2 (EZH2), found to be overexpressed in tumor endothelial cells,
methylates and inactivates vasohibin-1 (VASH1), a potent anti-angiogenic factor (8). We
recently demonstrated that silencing EZH2 with siRNA incorporated into chitosan (CH)
nanoparticles resulted in decreased angiogenesis and significant reduction in tumor growth
(9). Here, we examined the biological effects of combined metronomic PLGA-PRINT-
docetaxel and CH-mEZH2 siRNA in ovarian cancer models.
Gharpure et al. Page 2























Cell lines and culture
HeyA8, SKOV3ip1 and HeyA8-luciferase cells were maintained as described previously
(9). Briefly, the cells were maintained in 5% CO2 at 37°C in RPMI-1640 media
supplemented with 15% fetal bovine serum and 0.1% gentamycin sulfate. The cell lines
were obtained from The American Type Cell Collection and were routinely tested for
absence Mycoplasma.
Chitosan-mEZH2 siRNA
mEZH2-siRNA was incorporated into chitosan nanoparticles as described previously (8).
The nanoparticles were formulated based on ionic gelation of anionic tripolyphosphate
(TPP) and siRNA with cationic chitosan. Briefly, chitosan was dissolved in 0.25% acetic
acid. The nanoparticles were spontaneously formed after adding TPP (0.25% w/v) and
siRNA (1 μg/μL) to the chitosan solution under constant stirring at room temperature. The
nanoparticles were then incubated at 4°C for 40 min and then centrifuged at 12,000 RPM for
40 min at 4°C. The pellet was washed three times to remove any unbound chemicals or
siRNA. The nanoparticles thus formed were stored at 4°C until use.
PLGA-PRINT-docetaxel
PLGA-PRINT nanoparticles containing docetaxel were formulated as described previously
(6). Briefly, 150 μl of 10 mg/ml PLGA and 10 mg/ml docetaxel were spread on a 6″ × 12″
sheet of poly (ethylene terephthalate) (PET) using a Mayer Rod (R. D. specialties). The
solvent was evaporated with heat. The PET sheet was then placed in contact with the mold,
and the mold was separated from the sheet by passing the mold and sheet through a hot
laminator at 130°C and 80 psi (ChemInstruments Hot Roll Laminator). The mold was then
placed in contact with another PET sheet coated with 2000 g/mol polyvinyl alcohol
(PVOH). The nanoparticles were then transferred from the mold to the PET sheet by passing
through a hot laminator and finally removed from the PET sheet by passing the sheet
through rollers and applying water to dissolve the PVOH. The nanoparticles were purified
and later concentrated by tangential flow filtration (Spectrum Labs).
Particle characterization
The nanoparticles were characterized with use of a scanning electron microscope (SEM).
Briefly, a 50 μL nanoparticle sample was pipetted onto a glass slide. The sample was then
dried and coated with a 3 nm thick gold palladium alloy using a Cressington 108 auto-
sputter coater. Images were obtained with use of a Hitachi model S-4700 SEM at an
accelerating voltage of 2 kV. Size and polydispersity index were measured by using
dynamic light scattering (Malvern Instruments Nano-ZS).
Stability of PLGA-PRINT nanoparticles in plasma
Nanoparticles in phosphate bufferred saline were mixed with plasma at a 1:1 ratio and
shaken at 37°C. At set time points, nanoparticles were removed and washed with water 20
times by tangential flow filtration to remove plasma proteins (mPES hollow fiber filter with
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0.05 μm pore size, Spectrum Labs). The nanoparticles were then collected on a filter and
imaged. The nanoparticles were imaged by SEM (Hitachi S-47000 Cold Cathode Field
Emission Scanning Electron Microscope).
Drug loading
Docetaxel loading was measured with use of high performance liquid chromatography
(HPLC) with C18 reverse phase column (Agilent Technology series 1200). All of the
samples and standards of docetaxel and PLGA were prepared in acetonitrile. The
nanoparticle samples were prepared by diluting a sample at a ratio of 1 to 10 in acetonitrile.
A linear gradient of 100% water to 100% acetonitrile was run over for more than 10 min
followed by 100% acetonitrile for 5 min. The flow rate was 1 mL/min, and the wavelength
of detection was 205 nm.
In vitro drug release
We placed 100 μL of nanoparticle solution (200 μg/mL docetaxel) into a miniature dialysis
unit with a 20 k MW cutoff. The solution was dialyzed against a constantly stirred 1 L bath
of 1X PBS at 37°C. At each time point, the nanoparticle solution from each unit was
removed and centrifuged. The nanoparticle pellet was analyzed for the amount of docetaxel
remaining in the nanoparticles. By comparing this amount to the initial amount of docetaxel
present in the system, the percentage of drug release could be calculated.
Orthotopic model of ovarian cancer
Female athymic nude mice were purchased from Taconic Farms and housed in pathogen-
free conditions. They were cared for in accordance with the guidelines of the American
Association for Accreditation of Laboratory Animal Care and the U.S. Public Health Service
Policy on Human Care and Use of Laboratory Animals. All in vivo experiments and
protocols were approved by MD Anderson’s Institutional Animal Care and Use Committee.
For all of the in vivo experiments, cells were trypsinized at 60%-80% confluence,
centrifuged at 1200 RPM for 6 min at 4°C, washed twice with phosphate-buffered saline
(PBS), and reconstituted in Hanks balanced salt solution (HBSS) (Cellgro) to a desired
concentration (1.5 × 106 cells/mL for HeyA8 and 5 × 106 cells/mL for SKOV3ip1 for
intraperitoneal injections). For intraovarian injections, HeyA8-luciferase cells
(1.5×106cells/mL) were resuspended in 1:1 mixture of BD matrigel and HBSS). Mice were
anesthetized with ketamine and an incision was made just above the left ovary. A 1mL
tuberculin syringe with a 30-gauge needle was used to inject cells directly into the ovary.
The incision was then closed using surgical clips. The mice were returned to cages until full
recovery. The clips were removed after a week when the incision was fully healed.
The dose-finding studies for PLGA-PRINT-docetaxel were performed with five treatment
groups (10 mice/group) divided into a control (saline) group, maximum tolerated dose
(MTD- 20 mg/kg) group, and three groups at 0.5, 1.0, and 2.0 mg/kg of docetaxel injections.
Each mouse was injected intraperitoneally (i.p.) with 200 μL of cell suspension containing 3
× 105 HeyA8 cells. Treatment was started 1 week after the injections of tumor cells. A MTD
dose of 20 mg/kg was given once in 2 weeks during the entire in vivo treatment. Saline and
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metronomic doses of docetaxel were given as 200 μL i.p. injections three times per week.
The mice were monitored daily for any signs of toxic adverse effects. All the mice were
sacrificed when the mice in any group seemed to be moribund. Mouse weight, tumor weight
and the number of nodules were recorded.
For the therapeutic experiment, mice were divided into four groups (10 mice/group): CH-
control siRNA, CH-mEZH2 siRNA, PLGA-PRINT-docetaxel, and a combination of PLGA-
PRINT-docetaxel and CH-mEZH2 siRNA. The mice were injected i.p. with a 200 μL cell
suspension of either HeyA8 (3 × 105 cells/mouse) or SKOV3ip1 cells (1 × 106 cells/mouse).
Treatment was started 1 week after the tumor cell injections. The siRNA was injected at a
dose of 3.5 μg in 100 μL of saline intravenously (i.v.) twice weekly. The PLGA-PRINT-
docetaxel was injected at a dose of 0.5 mg/kg in 125 μL of saline i.p. three times weekly.
The mice were sacrificed when the mice in any group became moribund. Mouse weight,
tumor weight, and the number of tumor nodules were recorded. Tumors were collected and
the tissues were formalin-fixed or snap-frozen in optimal cutting medium for
immunohistochemical staining.
We performed additional therapeutic experiment with HeyA8-luciferese intraovarian mouse
model. The mice were injected with 100 μL suspension of HeyA8 cells (3 × 105 cells/
mouse). The mice were treated as mentioned earlier. Bioluminescence imaging was
conducted to monitor metastasis after initiation of treatments. Imaging and data acquisition
were performed with IVIS spectrum system coupled to the Living Image Software
(Xenogen, Alameda, CA). The mice were anesthetized in an acrylic chamber with a mixture
of 1% isoflurane in air. They were then injected intraperitoneally with luciferin potassium
salt (15 mg/mL) in PBS at a dose of 150 mg/kg body weight. A digital grayscale image was
initially acquired which was then overlaid with a pseudocolor image representing the spatial
distribution of detected photons emerging from active luciferase present within the animal.
Signal intensity was expressed as a sum of all photons detected per second.
Immunohistochemical staining
For immunohistochemical analysis, paraffin sections (5 μm) of tumor tissues were sectioned
and used for the detection of a proliferation marker (Ki67) and an apoptosis marker (cleaved
caspase 3). Frozen sections were used to detect the expression of an endothelial cell marker
(CD31). Formalin-fixed paraffin sections were deparaffinized by sequential washing with
xylene, 100% ethanol, 95% ethanol, 80% ethanol, and PBS. A suitable antigen retrieval
method was used. For CD31 staining, frozen cut sections were fixed by incubating for 5 min
in cold acetone, acetone + chloroform (1:1), and then cold acetone in a sequential manner.
No antigen retrieval procedure was necessary for CD31 staining. For all of the slides,
endogenous peroxide was blocked by incubating the slides with 3% hydrogen peroxide in
PBS. To prevent nonspecific binding of the primary antibody, the slides were incubated in
5% normal horse serum + 1% normal goat serum (for Ki67 and CD31 staining) or in 4% fish
gelatin in PBS (for cleaved caspase 3 staining) This was followed by an overnight
incubation at 4°C with a primary antibody diluted in the protein block solution. The primary
antibodies used were Ki67-rabbit polyclonal anti-human antibody from Thermo/lab vision,
cleaved caspase 3-rabbit polyclonal anti-human, mouse, rat from Biocare Medical, and
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CD31 rat anti-mouse antibody from Pharmingen/Invitrogen. After the slides were incubated
with primary antibodies, they were washed with PBS and incubated with suitable secondary
antibodies. For Ki67 and CD31 staining, goat anti-rabbit HRP antibody diluted in protein
block solution was used, and the slides were incubated in this solution for 1 h at room
temperature. For cleaved caspase 3 staining, the slides were first incubated with biotinylated
4+ goat anti-rabbit secondary antibody for 20 min, after which they were washed with PBS
and later incubated with streptavidin 4+ goat anti-rabbit secondary antibody for 20 min.
After the slides were incubated with secondary antibody, they were washed with PBS
followed by development with DAB (Research Genetics). The nuclei were stained with
Gill’s hematoxylin solution, and the slides were then mounted with paramount mounting
media.
For Ki67 and cleaved caspase staining, the number of tumor cells that were positive for
expression were counted. For CD31 staining, microvessel-like structures containing
endothelial cells that were positive for CD31 staining were counted. Expression was
quantified by using 15 random fields of slides at 100× magnification.
Statistical analysis
Continuous variables were analyzed with use of the Student’s t test or the Mann-Whiney U
test. A p value less than 0.05 was considered to be significant.
Results
PLGA-PRINT nanoparticle characterization
Before carrying out in vivo experiments, we first examined the PRINT nanoparticles, which
were of uniform size (80 × 320 nm) and shape as shown in Figure 1A. The percent docetaxel
loading, calculated by HPLC, was 17.1% (Figure 1B). When incubated with plasma, the
nanoparticles were stable up to 3 days (Figure 1C). The nanoparticles exhibited a “burst
release profile,” in which 100% of the drug is released within 24 hours (Figure 1D). We
performed cell viability experiments after incubation with PLGA-PRINT-nanoparticles.
There was no effect on cell viability after incubation with PRINT nanoparticles (data not
shown). We also conducted stability assays of the nanoparticles. The nanoparticles were
stable at −20°C up to 3 months while the lyophilized nanoparticles were stable at 4°C up to
6 months (Supplementary Table 1).
Internalization and stability assays of chitosan nanoparticles
We evaluated intracellular delivery of chitosan nanoparticles using HeyA8 cells and Cy3
labeled CH-control siRNA. There was efficient internalization of these nanoparticles into
the cancer cells (Supplementary Figure 1A). We also checked the stability of CH-mEZH2
siRNA in presence of 10% FBS. Naked siRNA was degraded rapidly upon incubation with
serum while siRNA protected by chitosan nanoparticles was not degraded (Supplementary
Figure 1B). To evaluate for any possible effects of the nanoparticles alone, we tested the
effect of chitosan nanoparticles on SKOV3ip1 cells. There was no effect on cell viability
after 48 hours of incubation with chitosan nanoparticles (Supplementary Figure 1C).
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Determining the optimal metronomic dose for PLGA-PRINT-docetaxel nanoparticles
Next, we conducted a dose-finding study to determine the lowest docetaxel dose that is
biologically effective. All of the doses were significantly effective in reducing the tumor
burden (p<0.05 for MTD and p<0.01 for metronomic doses). The lowest dose at 0.5 mg/kg
reduced the tumor weight by approximately 80% and was, therefore, chosen for subsequent
therapeutic studies (Figure 2A).
Therapeutic studies with metronomic doses
We next determined whether a combination of PLGA-PRINT-docetaxel nanoparticles with
CH-mEZH2 siRNA would result in a strong antitumor effect. The mice were divided into
the following groups: (a) CH-control siRNA, (b) CH-mEZH2 siRNA, (c) metronomic dose
of PLGA-PRINT-docetaxel (0.5 mg/kg), and (d) metronomic dose of PLGA-PRINT-
docetaxel and CH-mEZH2 siRNA. PLGA-PRINT-docetaxel was injected i.p. three times
weekly, whereas siRNA was injected i.v. twice weekly. CH-mEZH2 siRNA treatment
reduced aggregate tumor weight by approximately 70% in both HeyA8 and SKOV3ip1
models (p<0.01 for HeyA8 and p<0.05 for SKOV3ip1). PLGA-PRINT-docetaxel treatment
reduced tumor weight by ~80% (p<0.01). Combination therapy showed the greatest
therapeutic benefit with ~95% reduction in tumor weight in both models (p<0.001 in HeyA8
and p<0.01 in SKOV3 ip1). In the HeyA8 model, individual therapies resulted in reduction
in the number of nodules, and combination therapy showed a significant effect (p<0.01). In
the SKOV3ip1 model, combination therapy as well as individual therapies resulted in
significant reduction of tumor nodules (p<0.05) (Figures 2B and 2C). For the objective
evaluation of reduction of metastasis, we conducted an additional in vivo experiment with
luciferase labeled HeyA8 cells injected directly into the ovary. Bioluminescence imaging
revealed reduced metastasis after individual and combination therapies (Figures 3A and 3B).
No significant effects of therapy were noted on mouse weight or activity. Following siRNA
delivery, downregulation of murine EZH2 in endothelial cells was confirmed at mRNA level
by qRT-PCR and at protein level by immunohistochemistry (Supplementary Figures 1D and
1E).
Biological effects of metronomic PLGA-PRINT-docetaxel and CH-mEZH2 siRNA therapy
To determine the biological effects of combined therapy, in vivo samples were subjected to
immunohistochemical analysis for Ki67, cleaved caspase 3, and CD31 (Figure 3C).
Individual as well as combination therapies resulted in a significant reduction in
proliferation (p<0.001). Individual metronomic dosing of PLGA-PRINT-docetaxel and CH-
mEZH2 siRNA increased the apoptotic index significantly (p<0.05), whereas the
combination therapy had an additive effect (p<0.001). Previous studies have suggested that
metronomic chemotherapy affects endothelial cell proliferation. To test this hypothesis,
frozen tumor sections from the in vivo studies were stained for CD31. CH-mEZH2 siRNA as
well as metronomic PLGA-PRINT-docetaxel therapy showed a significant effect on tumor
vasculature (p<0.01). Combining CH-mEZH2 siRNA with metronomic docetaxel also
resulted in a significant reduction in microvessel density (p<0.01).
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The key finding from this study is the pronounced antitumor effect of metronomic delivery
of PLGA-PRINT-docetaxel therapy along with CH-mEZH2 siRNA. We have previously
shown that the major biological effect of metronomic therapy is through its anti-angiogenic
effects (8, 10). Concordant with those studies, we saw a significant anti-angiogenic effect
and downstream anti-proliferative and pro-apoptotic effects.
Metronomic chemotherapy has been proposed to serve as an alternative to the standard
dosing schedule to overcome the problems associated with the latter. Long-term
administration of standard chemotherapies is limited by their toxic effects on normal cells,
whereas metronomic therapy has minimal adverse effects (2–5, 11). Metronomic dosing has
also been shown to be effective against chemoresistant models (12, 13). Whereas standard
therapy has little effect on tumor vasculature, studies have shown that metronomic therapy
has significant anti-angiogenic effects (2–5, 11–14). Our findings from this study also
suggest that endothelial cells are quite sensitive to low doses of docetaxel therapy in a
metronomic schedule. Moreover, the low toxicity profile of metronomic dosing makes it a
suitable candidate for combination therapies. Several studies have demonstrated that a
combination of metronomic dosing with an anti-angiogenic therapy has significant anti-
tumor effects in ovarian cancer (10, 13, 15, 16). Here, we provide strong evidence that
metronomic docetaxel dosing with novel PRINT nanoparticles has strong anti-proliferative,
anti-apoptotic, and anti-angiogenic effects and that combining it with CH-mEZH2 siRNA
proved to be highly efficacious in reducing tumor burden.
Angiogenesis is one of the key processes that promotes cancer growth and metastasis. The
process is regulated by several pro and anti-angiogenic factors in the body that become
deregulated in cancer (17). EZH2 was found to be overexpressed in tumor-associated
endothelial cells (8). Previous studies in our laboratory (9) have shown that VEGF directly
increases EZH2 expression on endothelial cells, which in turn methylates and inhibits an
anti-angiogenic factor, vasohibin-1 (VASH1). Several other studies have shown that EZH2
plays a critical role in several oncogenic pathways (18–21). Hence, silencing EZH2 in
endothelial cells is a promising therapeutic approach to target angiogenesis.
With increasing understanding of toxicity profiles and because of the poor pharmacokinetic
properties of the current chemotherapeutics, there is a need to develop a delivery vehicle
with improved drug efficacy and reduced toxicity. Docetaxel is a commonly used
chemotherapeutic agent but is often associated with systemic toxicities. When compared
with docetaxel alone, PLGA-PRINT nanoparticles loaded with docetaxel showed higher
plasma exposure, higher tumor concentration and lower volume of distribution in a
subcutaneous ovarian cancer mouse model (6). It also exhibited a characteristic “burst
release profile,” in which 100% of the drug is released within 24 hours. This property is
ideal for metronomic drug delivery.
In summary, we have demonstrated that combination therapy of metronomic PLGA-PRINT-
docetaxel and CH-mEZH2siRNA is highly effective in reducing tumor burden. This
approach holds great potential for new treatment strategies for ovarian and other cancers.
Gharpure et al. Page 8























Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial Information
K.G. is supported by Altaman Goldstein Discovery Fellowship. S.Y.W. is supported by Ovarian Cancer Research
Fund, Foundation for Women’s Cancer, and Cancer Prevention Research Institute of Texas training grants
(RP101502, RP101489 and RP110595). Portions of this work were supported by the NIH (U54 CA151668,
CA016672, CA109298, P50 CA083639, P50 CA098258, and UH2 TR000943-01), the DOD (OC120547 and
OC093416), the Ovarian Cancer Research Fund (Program Project Development Grant), the Blanton-Davis Ovarian
Cancer Research Program, Meyer and Ida Gordon Foundation #2, the RGK Foundation, the Gilder Foundation, and
the Betty Anne Asche Murray Distinguished Professorship.
We thank D. Reynolds and Dr. R. Langley for technical assistance and helpful discussions.
References
1. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat
Rev Cancer. 2003; 3:502–16. [PubMed: 12835670]
2. Gasparini G. Metronomic scheduling: the future of chemotherapy? The Lancet Oncology. 2001;
2:733–40. [PubMed: 11902515]
3. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs
can target tumor angiogenesis in mice. The Journal of Clinical Investigation. 2000; 105:1045–7.
[PubMed: 10772648]
4. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer.
2004; 4:423–36. [PubMed: 15170445]
5. Romiti A, Cox MC, Sarcina I, Rocco R, D’Antonio C, Barucca V, et al. Metronomic chemotherapy
for cancer treatment: a decade of clinical studies. Cancer Chemotherapy and Pharmacology. 2013;
72:13–33. [PubMed: 23475105]
6. Enlow EM, Luft JC, Napier ME, DeSimone JM. Potent engineered PLGA nanoparticles by virtue of
exceptionally high chemotherapeutic loadings. Nano Lett. 2011; 11:808–13. [PubMed: 21265552]
7. Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, et al. Plasma, tumor and tissue
pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice
bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine. 2013; 9:686–93. [PubMed:
23219874]
8. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, et al. Gene Alterations Identified by
Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma.
Cancer Research. 2007; 67:1757–68. [PubMed: 17308118]
9. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor
angiogenesis by EZH2. Cancer Cell. 2010; 18:185–97. [PubMed: 20708159]
10. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, et al. Bridging the Gap between
Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer.
Molecular Cancer Therapeutics. 2010; 9:985–95. [PubMed: 20371710]
11. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy
with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt
toxicity. J Clin Invest. 2000; 105:R15–24. [PubMed: 10772661]
12. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, et al. Antiangiogenic
scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer
Res. 2000; 60:1878–86. [PubMed: 10766175]
13. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, et al. Metronomic chemotherapy
enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007; 67:281–8.
[PubMed: 17210709]
Gharpure et al. Page 9






















14. Merritt WM, Danes CG, Shahzad MMK, Lin YG, Kamat AA, Han LY, et al. Anti-angiogenic
properties of metronomic topotecan in ovarian carcinoma. Cancer Biology & Therapy. 2009;
8:1596–603. [PubMed: 19738426]
15. Aigner J, Bischofs E, Hallscheidt P, Sohn C, Schneeweiss A, Eichbaum M. Long-term remission in
a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and
metronomic cyclophosphamide treatment. Anticancer Drugs. 2011; 22:1030–3. [PubMed:
21970854]
16. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of
metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the
treatment of ovarian cancer. Mol Cancer Ther. 2010; 9:996–1006. [PubMed: 20371722]
17. Folkman J. What Is the Evidence That Tumors Are Angiogenesis Dependent? Journal of the
National Cancer Institute. 1990; 82:4–7. [PubMed: 1688381]
18. Guo J, Cai J, Yu L, Tang H, Chen C, Wang Z. EZH2 regulates expression of p57 and contributes
to progression of ovarian cancer in vitro and in vivo. Cancer Science. 2011; 102:530–9. [PubMed:
21205084]
19. Rao Z-Y, Cai M-Y, Yang G-F, He L-R, Mai S-J, Hua W-F, et al. EZH2 supports ovarian
carcinoma cell invasion and/or metastasis via regulation of TGF-β1 and is a predictor of outcome
in ovarian carcinoma patients. Carcinogenesis. 2010; 31:1576–83. [PubMed: 20668008]
20. Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, et al. EZH2 blockade by
RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1
and by inhibiting mutant p53. Cancer letters. 2013; 336:53–60. [PubMed: 23603558]
21. Tsang DPF, Cheng ASL. Epigenetic regulation of signaling pathways in cancer: Role of the
histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology. 2011; 26:19–27.
[PubMed: 21175789]
Gharpure et al. Page 10























Particle characterization, drug loading and release profile: (A) 80 × 320 nm PLGA-PRINT-
docetaxel nanoparticles- Scanning electron microscopy (SEM) image. (B) Size, PDI and
drug loading profile. (C) Stability of PLGA-PRINT nanoparticles after incubation with
plasma. SEM images are shown. Nanoarticles before (top left panel) and after (top right
panel) plasma exposure for 1 day. Nanoparticles after 3 days in plasma (Bottom left panel).
Nanoparticles after 7 days in plasma (Bottom right panel). (D) In vitro drug release profile.
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Dose determination and therapeutic in vivo experiments: (A) Dose finding study: Effect of
metronomic (0.5, 1, 2 mg/kg) versus MTD doses (20 mg/kg) of PLGA-PRINT-docetaxel
therapy on HeyA8 orthotopic mouse model. Average of tumor weight and number of
nodules are shown. All the metronomic doses showed significant tumor reduction. Error
bars represent S.E.M. *p<0.05, **p<0.01 compared to saline. Tumor growth inhibition with
CH-mEZH2 siRNA and PLGA-PRINT-docetaxel, alone and with combination therapy in
HeyA8 (B) and SKOV3ip1 (C) orthotopic mouse model. Average of tumor weights and
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number of nodules are shown. Combination therapy showed the greatest therapeutic benefit
in both mouse models. There was significant reduction in tumor weight as well as in tumor
nodules. Error bars represent S.E.M. *p<0.05, **p<0.01, ***p<0.001 compared to CH-
control siRNA group.
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Biologicals effects of the treatments: (A) Noninvasive images of metastasis and tumor
growth in orthotopic mouse model of HeyA8. Representative images show reduction in
metastasis after the treatment of CH-mEZH2 siRNA, PLGA-PRINT-docetaxel and
combination therapy. The effect is pronounced in the combination group. Quantification of
luciferin signal intensity is shown in the adjoining graph. Error bars represent S.E.M.
*p<0.05, **p<0.01. (B) Representative images of sites of metastasis and tumor burden in
orthotopic mouse model of HeyA8. The data shows reduction in metastasis after individual
and combination therapies. (C) Proliferation index (Ki67), apoptosis index (cleaved caspase
3) and microvessel density (CD31) in HeyA8 tumors treated with CH-control siRNA, CH-
mEZH2 siRNA, PLGA-PRINT-docetaxel and combination therapy. A graphic
representation of the average number of Ki67 or cleaved caspase 3 positive cells and CD31
positive vessels are shown in the adjoining graphs. Combination therapy showed significant
anti-proliferative, pro-apoptotic and anti-angiogenic effects. Error bars represent S.E.M.
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*p<0.05, **p<0.01, ***p<0.001 compared to CH-control siRNA group. The scale bar
represents 100 μm.
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